Biocon

Q4 FY25Pharmaceuticals & Biotechnology

Biocon Q4 FY25 earnings call: Revenue & Margins

Q4 FY25 earnings call: what management guided on revenue, margins and order book.

Price₹416

Market cap₹67.7K Cr

P/E93.1

Updated23 Aug 2026

Read4 min read

The short version

Biosimilars: Expect accelerated growth driven by new biosimilar launches with increasing market shares, e.g., Stelara and insulins expanding across 80+ countries. FY'25 saw a consolidation and transition phase setting up for accelerated growth, with a 10% YoY increase in revenue and 16% YoY growth in core EBITDA (Page 5,7).

From Biocon's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Biosimilars: Expect accelerated growth driven by new biosimilar launches with increasing market shares, e.g., Stelara and insulins expanding across 80+ countries. Four biosimilars each crossed USD 200 million revenue, indicating strong adoption and future growth. (Pages 6, 13, 17)
Generics: Growth supported by multiple upcoming product launches including liraglutide in Europe and the U.S., generic Copaxone, Everolimus (Zortress), and continued volumes from generic lenalidomide starting FY '26. (Pages 15, 10)
Insulin: Significant surge in global demand with capacity doubling in Malaysia; poised to become one of the largest fully integrated insulin manufacturers. Innovators withdrawing from certain markets opens opportunities. (Pages 15, 17, 13)

2 more points management made on revenue & sales performance

Profitability & Margins

FY'25 saw a consolidation and transition phase setting up for accelerated growth, with a 10% YoY increase in revenue and 16% YoY growth in core EBITDA (Page 5,7).
New biosimilar launches (e.g., Yesintek™) and Generics growth (Lenalidomide, Liraglutide) expected to drive stronger revenue and EBITDA growth ahead (Pages 6,15).
Incremental gross margin and EBITDA improvement anticipated from upcoming launches, supporting better profitability and operating leverage (Page 10).
R&D spend expected to moderate post ongoing development phases, stabilizing as a percentage of sales (Page 14).
Capex largely ramped up for capacity expansions (e.g., Malaysia insulin, peptide API), with reduced maintenance Capex forecasted beyond FY'26 (Pages 14,16).

2 more points management made on profitability & margins

See what Biocon said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Biocon plans to spend about USD 100 million in Capex over the next couple of years, primarily to enhance biologics capacities in Malaysia (Page 14).
A large part of this Capex focuses on increasing insulin manufacturing capacity, including a twofold expansion of drug product and drug substance capacities in Malaysia (Page 15).
For Generics, next year’s Capex is estimated at around USD 50 million, mostly maintenance Capex, with major ongoing programs concluding (Page 14).

2 more points management made on capital expenditure plans

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential

1Accretion Pharmaceuticals Ltd₹226 Cr

Rev 1Mar 2

2OneSource Specialty Pharma Ltd₹17.3K Cr

Rev 1Mar 3

3₹297 Cr

Rev 2Mar 1

4₹6.7K Cr

Rev 2Mar 2

5₹2.3K Cr

Rev 2Mar 2

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

Biocon plans to raise INR 4,500 crores through a combination of Qualified Institutional Placement (QIP) and private placement.
Shareholders' notice for the capital raise was sent recently, and discussions with bankers, investors, and lawyers are ongoing.
The first tranche of the fundraising is expected to be completed by mid-June 2025.

2 more points management made on fundraising & capital structure

See what Biocon said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript of Biocon Limited's Q4 FY25 earnings call does not provide specific details or figures related to the current or expected order book or pending orders. The discussion mainly revolves around product launches, regulatory approvals, capacity expansions, financial performance, strategic options including potential mergers, and market access updates. No explicit information on order book status or pending orders was mentioned in the sections provided.

Biocon — Quarterly revenue & net profit

Revenue Net profit Net loss

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹4.5K Cr, net profit ₹199 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Biocon's management said in earlier quarters

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Biocon Q4 FY25 results?

What is Biocon share price analysis?

Biocon currently shows a neutral. The stock trades at a P/E of 93.1 with a market cap of ₹67,722 Cr. Investors should review the full earnings analysis for detailed insights.

Is Biocon planning capital expenditure?

Biocon plans to spend about USD 100 million in Capex over the next couple of years, primarily to enhance biologics capacities in Malaysia (Page 14).

Keep Biocon on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.